Open-angle glaucoma<unk>  eye drops, marketed by Pfizer<unk>  in Japanese-language packaging In people with ocular hypertension (intraocular pressure (IOP) ≥21 mm Hg) including open-angle glaucoma, treatment with<unk>  reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment.<unk>  was more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials.<unk>  demonstrated a stable long-term IOP-lowering effect in 1- or 2-year continuations of these trials, with no sign of diminishing effect during prolonged treatment. Meta-analysis suggests that<unk>  is more effective than timolol in lowering intraocular pressure (IOP). However, it often causes iris pigmentation. While current evidence suggests that this pigmentation is benign, careful lifetime evaluation of patients is still justified. Closed-angle glaucoma Patients who had elevated IOP despite iridotomy and/or iridectomy (including patients of Asian descent),<unk>  was significantly more effective than timolol in two double-blind, monotherapy trials (8.2 and 8.8 mm Hg vs 5.2 and 5.7 mm Hg for<unk>  vs timolol at 12 and 2 weeks, respectively).
Latanoprost
Travoprost
Carboprost
Iloprost
Bimatoprost
Travoprost/timolol
Bimatoprost/timolol
Bifluranol